<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="127762">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01922375</url>
  </required_header>
  <id_info>
    <org_study_id>FLV_BPH_IV-1</org_study_id>
    <nct_id>NCT01922375</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia</brief_title>
  <official_title>A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dong-A Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dong-A Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>South Korea: Korea Food and Drug Administration (KFDA)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of Naftopidil in Korean male
      patients with with lower urinary tract symptoms associated with benign prostatic
      hyperplasia.

      The investigators hypothesized that Naftopidil which came onto marcket in Japan would effect
      in improvement of voiding and storage difficulty.

      Design:

      Placebo-controlled, Randomized, Double-blind, Double-dummy, Parallel group, Fixed dose
      design
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Efficacy(IPSS score change)</measure>
    <time_frame>From 0 week(baseline) to 12 week(end of the treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy(IPSS, Uroflowmetry parameter, LUTS-GAQ)</measure>
    <time_frame>From 0 week(baseline) to 12 week(end of the treatment)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">411</enrollment>
  <condition>Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia</condition>
  <arm_group>
    <arm_group_label>Naftopidil dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Naftopidil dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PO administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naftopidil</intervention_name>
    <arm_group_label>Naftopidil dose 2</arm_group_label>
    <arm_group_label>Naftopidil dose 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patients aged 4 years or more diagnosed with BPH

        Exclusion Criteria:

          -  subjects with uncontrolled blood pressure

          -  subjects with hepatic or renal dysfunction

          -  subjects with prostate cancer

          -  Had treatments for BPH using other alpha receptor antagonists within 2 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sae-Woong Kim, MD.PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul St. Mary's Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jae-Seok Hyun, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gyeongsang National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Du-Geon Moon, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nam-Cheol Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pusan National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sung-Won Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Soo-Woong Kim, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tai-Young Ahn, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ki-Hak Moon, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yeongnam University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Woo-Sik Chung, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kweon-Sik Min, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong Kwan Park, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chonbuk National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dae Yul Yang Yang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ji- Kan Ryu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inha University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam national university hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 11, 2013</lastchanged_date>
  <firstreceived_date>February 11, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Naftopidil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
